Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance

While great strides have been made in the treatment of advanced renal cell carcinoma (RCC) with the emergence of immune checkpoint inhibitors (ICIs) and VEGFR-targeting drugs, sizable proportions of patients still do not respond to upfront therapy and long-term responses only occur in a minority of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenfeld, David A., Merkin, Ross D., Moutafi, Myrto, Martinez, Sandra, Adeniran, Adebowale, Kumar, Deepika, Jilaveanu, Lucia, Hurwitz, Michael, Rimm, David L., Kluger, Harriet M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608089/
https://www.ncbi.nlm.nih.gov/pubmed/36313654
http://dx.doi.org/10.3389/fonc.2022.990367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608089/
https://www.ncbi.nlm.nih.gov/pubmed/36313654
http://dx.doi.org/10.3389/fonc.2022.990367

Ejemplares similares